Abstract
Monoamine oxidase type B inhibitors (MAOBIs), such as selegiline (Eldepryl and generics), have been used in both early and later Parkinson disease (PD)
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
